Paul Alloway - 25 Mar 2024 Form 4 Insider Report for Homology Medicines, Inc. (QTTB)

Role
President and Chief Operating Officer
Signature
/s/ Paul Alloway
Issuer symbol
QTTB
Transactions as of
25 Mar 2024
Net transactions value
$0
Form type
4
Filing time
27 Mar 2024, 16:15:14 UTC
Previous filing
05 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FIXX Common Stock Options Exercise +23,530 +84% 51,566 25 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FIXX Restricted Stock Units Options Exercise $0 -5,440 -100% $0.000000* 0 25 Mar 2024 Common Stock 5,440 Direct F1, F2
transaction FIXX Restricted Stock Units Options Exercise $0 -18,090 -100% $0.000000* 0 25 Mar 2024 Common Stock 18,090 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Paul Alloway is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2 The vesting of these RSUs has been accelerated such that the RSUs vested in full on March 25, 2024, immediately prior to the Effective Time as defined in that certain Agreement and Plan of Merger by and among the Issuer, Kenobi Merger Sub, Inc. and Q32 Bio Inc. dated November 16, 2023.

Remarks:

President and Chief Operating Officer